Modality
Nanobody
MOA
EZH2i
Target
VEGF
Pathway
mTOR
FTD
Development Pipeline
Preclinical
~Nov 2013
→ ~Feb 2015
Phase 1
~May 2015
→ ~Aug 2016
Phase 2
~Nov 2016
→ ~Feb 2018
Phase 3
May 2018
→ Feb 2030
Phase 3Current
NCT08930071
2,613 pts·FTD
2022-11→2030-02·Recruiting
NCT06009027
1,922 pts·FTD
2024-04→2025-12·Not yet recruiting
NCT07377268
2,391 pts·FTD
2018-05→2029-01·Not yet recruiting
+1 more trial
7,966 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-12-223mo agoPh3 Readout· FTD
2028-10-072.5y awayPh3 Readout· FTD
2029-01-042.8y awayPh3 Readout· FTD
2030-02-133.9y awayPh3 Readout· FTD
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P3
Not yet…
P3
Recruit…
P3
Not yet…
P3
Active
Catalysts
Ph3 Readout
2025-12-22 · 3mo ago
FTD
Ph3 Readout
2028-10-07 · 2.5y away
FTD
Ph3 Readout
2029-01-04 · 2.8y away
FTD
Ph3 Readout
2030-02-13 · 3.9y away
FTD
RecruitingActiveNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08930071 | Phase 3 | FTD | Recruiting | 2613 | DAS28 |
| NCT06009027 | Phase 3 | FTD | Not yet recr... | 1922 | ORR |
| NCT07377268 | Phase 3 | FTD | Not yet recr... | 2391 | SRI-4 |
| NCT04653078 | Phase 3 | FTD | Active | 1040 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF |